| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
A probe containing an aspartic acid peptide linker (D11) as a carrier to bone metastases, an RGD peptide [c(RGDfK) peptide] as a carrier to the primary cancer, and Ga-DOTA as a stable radiometal complex for imaging in one molecule, 67Ga-DOTA-D11-c(RGDfK), was prepared and evaluated to detect both the primary cancer and bone metastases simultaneously. Biodistribution experiments and single photon emission tomography (SPECT) imaging using tumor-bearing mice were performed. 67Ga-DOTA-D11-c(RGDfK) exhibited high uptake in bone and tumor. The accumulation of 67Ga-DOTA-D11-c(RGDfK) in tumor decreased when it was co-injected with c(RGDfK) peptide. Since 90Y-DOTA-D11-c(RGDfK) showed similar characteristics, they have great potential as theranostics system for diagnosis and therapy of both the primary cancer and bone metastases simultaneously.
|
